Clinical Trials Logo

Junctional Epidermolysis Bullosa clinical trials

View clinical trials related to Junctional Epidermolysis Bullosa.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03578029 Terminated - Clinical trials for Dystrophic Epidermolysis Bullosa

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

CELEB
Start date: May 22, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB).

NCT ID: NCT03490331 Terminated - Clinical trials for Junctional Epidermolysis Bullosa

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)

HOLOGENE17
Start date: March 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective open-label, uncontrolled clinical study to assess the safety and efficacy of autologous cultured epidermal grafts containing epidermal stem cells genetically modified with the aid of a gamma-retroviral vector carrying COL17A1 complementary DNA (cDNA) for restoration of the epidermis in patients with junctional epidermolysis bullosa. The purpose of this study is to demonstrate the safety and efficacy after one or more treatments with genetically corrected cultured epidermal autograft (Hologene 17) in patients suffering of junctional epidermolysis bullosa (JEB) with COL17A1 mutation.